[go: up one dir, main page]

FR2725726B1 - Vecteurs viraux et utilisation en therapie genique - Google Patents

Vecteurs viraux et utilisation en therapie genique

Info

Publication number
FR2725726B1
FR2725726B1 FR9412346A FR9412346A FR2725726B1 FR 2725726 B1 FR2725726 B1 FR 2725726B1 FR 9412346 A FR9412346 A FR 9412346A FR 9412346 A FR9412346 A FR 9412346A FR 2725726 B1 FR2725726 B1 FR 2725726B1
Authority
FR
France
Prior art keywords
gene therapy
viral vectors
viral
vectors
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9412346A
Other languages
English (en)
Other versions
FR2725726A1 (fr
Inventor
Michel Perricaudet
Martin Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9412346A priority Critical patent/FR2725726B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to CA002201399A priority patent/CA2201399A1/fr
Priority to JP51298396A priority patent/JP3816952B2/ja
Priority to AU36584/95A priority patent/AU712243B2/en
Priority to PCT/FR1995/001326 priority patent/WO1996012030A1/fr
Priority to US08/817,494 priority patent/US6669942B2/en
Priority to EP95934200A priority patent/EP0787198A1/fr
Priority to IL11558495A priority patent/IL115584A/xx
Priority to ZA958686A priority patent/ZA958686B/xx
Publication of FR2725726A1 publication Critical patent/FR2725726A1/fr
Application granted granted Critical
Publication of FR2725726B1 publication Critical patent/FR2725726B1/fr
Priority to NO971590A priority patent/NO971590L/no
Priority to FI971613A priority patent/FI971613L/fi
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR9412346A 1994-10-17 1994-10-17 Vecteurs viraux et utilisation en therapie genique Expired - Fee Related FR2725726B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR9412346A FR2725726B1 (fr) 1994-10-17 1994-10-17 Vecteurs viraux et utilisation en therapie genique
JP51298396A JP3816952B2 (ja) 1994-10-17 1995-10-11 治療遺伝子と免疫保護遺伝子とを含む欠陥アデノウイルス
AU36584/95A AU712243B2 (en) 1994-10-17 1995-10-11 Defective adenoviruses including a therapeutic gene and an immunoprotective gene
PCT/FR1995/001326 WO1996012030A1 (fr) 1994-10-17 1995-10-11 Adenovirus defectifs comprenant un gene therapeutique et un gene immunoprotecteur
US08/817,494 US6669942B2 (en) 1994-10-17 1995-10-11 Defective adenoviruses including a therapeutic gene and an immunoprotectove gene
EP95934200A EP0787198A1 (fr) 1994-10-17 1995-10-11 Adenovirus defectifs comprenant un gene therapeutique et un gene immunoprotecteur
CA002201399A CA2201399A1 (fr) 1994-10-17 1995-10-11 Adenovirus defectifs comprenant un gene therapeutique et un gene immunoprotecteur
IL11558495A IL115584A (en) 1994-10-17 1995-10-12 Replication defective adenoviral vectors with low immunogenicity capable of prolonged expression of a coding sequence comprised therein
ZA958686A ZA958686B (en) 1994-10-17 1995-10-13 Viral vectors and use in gene therapy
NO971590A NO971590L (no) 1994-10-17 1997-04-07 Defektive adenovirus omfattende et terapeutisk gen og et immunobeskyttende gen
FI971613A FI971613L (fi) 1994-10-17 1997-04-16 Defektiivisiä adenoviruksia, jotka käsittävät terapeuttisen geenin ja immunoprotektiivisen geenin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9412346A FR2725726B1 (fr) 1994-10-17 1994-10-17 Vecteurs viraux et utilisation en therapie genique

Publications (2)

Publication Number Publication Date
FR2725726A1 FR2725726A1 (fr) 1996-04-19
FR2725726B1 true FR2725726B1 (fr) 1997-01-03

Family

ID=9467911

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9412346A Expired - Fee Related FR2725726B1 (fr) 1994-10-17 1994-10-17 Vecteurs viraux et utilisation en therapie genique

Country Status (11)

Country Link
US (1) US6669942B2 (fr)
EP (1) EP0787198A1 (fr)
JP (1) JP3816952B2 (fr)
AU (1) AU712243B2 (fr)
CA (1) CA2201399A1 (fr)
FI (1) FI971613L (fr)
FR (1) FR2725726B1 (fr)
IL (1) IL115584A (fr)
NO (1) NO971590L (fr)
WO (1) WO1996012030A1 (fr)
ZA (1) ZA958686B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6816194A (en) * 1993-04-20 1994-11-08 Robinson, William S. Methods and materials for treatment of individuals infected with intracellular infectious agents
US6372208B1 (en) 1999-09-28 2002-04-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US6251957B1 (en) 1995-02-24 2001-06-26 Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
ATE352634T1 (de) * 1995-02-24 2007-02-15 Univ Pennsylvania Benutzung von immunmodulatoren zur herstellung von medikamenten zur inhibierung einer immunantwort gegen gleichzeitig verabreichte rekombinante viren
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
ATE445705T1 (de) * 1995-06-15 2009-10-15 Crucell Holland Bv Verpackungssysteme für humane rekombinante adenoviren zur gentherapie
AUPN477695A0 (en) * 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
WO1998000166A1 (fr) * 1996-07-03 1998-01-08 Merial, Inc. ADENOVIRUS CANIN DE RECOMBINAISON (ACR) CONTENANT DE l'ADN EXOGENE
AU4255397A (en) * 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
CA2308017A1 (fr) 1997-10-30 1999-05-14 Erik S. Falck-Pedersen Procede inhibant la reponse immunitaire a un vecteur recombine
US20040043489A1 (en) * 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
CA2365911A1 (fr) * 1999-04-09 2000-10-19 Schering-Plough Ltd. Adenovirus recombinants et mutants derives de l'adenovirus type 1 bovin
US6451319B1 (en) 1999-04-09 2002-09-17 Schering-Plough Veterinary Corporation Recombinant and mutant adenoviruses
NZ515582A (en) * 1999-05-17 2003-11-28 Crucell Holland B Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
GB9924981D0 (en) 1999-10-21 1999-12-22 Univ Manchester Gene therapy
CN1254719A (zh) * 1999-11-19 2000-05-31 钱其军 一种缺陷型腺病毒及其构建方法
EP1157999A1 (fr) * 2000-05-24 2001-11-28 Introgene B.V. Méthodes et moyens pour améliorer la transplantation de la peau en utilisant des vecteurs d'apport de genes munis d'un tropisme pour des fibroblastes primaires ainsi que d'autres utilisations de celles-ci
US20040033605A1 (en) * 2000-09-20 2004-02-19 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
EP1203819A3 (fr) 2000-10-06 2002-08-07 Transgene S.A. Vecteurs anti-inflammatoires
KR100432953B1 (ko) * 2001-09-01 2004-05-28 김주항 개선된 종양 살상 효과를 나타내는 재조합 아데노바이러스
JP4495587B2 (ja) * 2002-04-25 2010-07-07 クルセル ホランド ベー ヴェー 組換えアデノウイルスベクターおよびその使用
US8420611B2 (en) 2004-08-12 2013-04-16 Cedars-Sinai Medical Center Combined gene therapy for the treatment of macroscopic gliomas
WO2007086879A2 (fr) 2005-02-11 2007-08-02 University Of Southern California Procedes d’expression de proteines avec des ponts disulfure
US20060286074A1 (en) * 2005-05-31 2006-12-21 Yucheng Tang Methods for immunotherapy of cancer
JP2009514536A (ja) * 2005-11-07 2009-04-09 シドニー キンメル キャンサー センター Ｃｄ４０リガンド融合蛋白質ワクチン
WO2008095027A2 (fr) 2007-01-30 2008-08-07 Cedars-Sinai Medical Center Vecteur adenoviral comprenant une thymidine kinase de virus herpes simplex virus type 1 et un transgene pour augmenter l'expression du transgene
WO2010056901A2 (fr) 2008-11-13 2010-05-20 University Of Southern California Procédé d'expression de protéines avec ponts disulfure avec des rendements et une activité améliorés
EP2421563B1 (fr) 2009-04-22 2017-04-12 Massachusetts Institute of Technology Suppression immunitaire innée permettant la distribution répétée de longues molécules d'arn
US10837020B2 (en) * 2009-04-22 2020-11-17 Massachusetts Institute Of Technology Innate immune suppression enables repeated delivery of long RNA molecules
US20120237481A1 (en) * 2011-03-17 2012-09-20 Xiaoliu Zhang Incorporation of the B18R gene to enhance antitumor effect of virotherapy
US8445781B1 (en) 2011-11-15 2013-05-21 Nova D. Chasser Electrical receptacle cover having safety bracket for use with fragrance dispenser
US10329586B2 (en) 2016-09-20 2019-06-25 Boehringer Ingelheim Vetmedica Gmbh Canine adenovirus vectors
EP3515480A1 (fr) 2016-09-20 2019-07-31 Boehringer Ingelheim Vetmedica GmbH Nouveau vaccin contre la grippe porcine
EA201990711A1 (ru) 2016-09-20 2019-09-30 Бёрингер Ингельхайм Ветмедика Гмбх Новый ehv сайт инсерции orf70
MY199909A (en) 2016-09-20 2023-11-29 Boehringer Ingelheim Vetmedica Gmbh Promoters
US11839655B2 (en) 2017-09-01 2023-12-12 Microvax, Llc Combination cancer therapy
EP4221738A1 (fr) 2020-09-30 2023-08-09 Alma Bio Therapeutics Thérapie par acide nucléique pour la modulation différentielle de la microflore hôte

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE230615T1 (de) * 1991-10-04 2003-01-15 Whitehead Biomedical Inst Regulierung der systemischen immunantworten mittels zytokinen und antigenen
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1994004196A1 (fr) * 1992-08-14 1994-03-03 Imperial Cancer Research Technology Limited Therapie de tumeurs
EP0905253A3 (fr) * 1992-12-03 2000-11-02 Genzyme Corporation Vecteur adenovira délété de tous les ORF de E4 excepté ORF6
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.

Also Published As

Publication number Publication date
AU3658495A (en) 1996-05-06
IL115584A (en) 2005-11-20
FI971613A0 (fi) 1997-04-16
NO971590D0 (no) 1997-04-07
JP3816952B2 (ja) 2006-08-30
CA2201399A1 (fr) 1996-04-25
FI971613L (fi) 1997-04-16
ZA958686B (en) 1996-05-22
FR2725726A1 (fr) 1996-04-19
US6669942B2 (en) 2003-12-30
WO1996012030A1 (fr) 1996-04-25
NO971590L (no) 1997-04-07
IL115584A0 (en) 1996-01-19
EP0787198A1 (fr) 1997-08-06
JPH10507079A (ja) 1998-07-14
AU712243B2 (en) 1999-11-04
US20020006395A1 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
FR2725726B1 (fr) Vecteurs viraux et utilisation en therapie genique
FR2707664B1 (fr) Vecteurs viraux et utilisation en thérapie génique.
EP0688358A4 (fr) Vecteurs ameliores en therapie genique
FI955552L (fi) Adenoviraalisia eläinperäisiä vektoreita ja niiden käyttö geeniterapiassa
IL111681A0 (en) Recombinant viruses and their use in gene therapy
FI963246L (fi) Geeniterapiassa käytettävä isäntävektorijärjestelmä
FI951138L (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
ZA951803B (en) Recombinant viruses their preparation and their therapeutic use
EP0623020A4 (fr) Pyropheophorbides et leur utilisation en therapie photodynamique.
FI955154L (fi) Viruskombinantteja ja niiden käyttö geeniterapiassa
NO943344D0 (no) MN-gen og -protein
DK0941056T3 (da) Sphingomyelinasepræparater samt anvendelse deraf
NO972236D0 (no) Dihydropyrimidiner og anvendelse derav
ZA952563B (en) Recombinant viruses their preparation and their use in gene therapy
DE69526002D1 (de) Aufladegerät und Aufladevorrichtung
IL111682A0 (en) Recombinant viruses and their use in gene therapy
IT1291135B1 (it) Vettori ricombinanti utilizzabili in terapia genica
PT983271E (pt) Hemissulfato carbociclico nucleosidico e a sua utilizacao no tratamento de infeccoes virais
FR2725213B1 (fr) Vecteurs viraux et utilisation en therapie genique
IL117466A0 (en) Recombinant viruses expressing lecithin-cholesterol acryltransferase and their use in gene therapy
KR950700316A (ko) 재조합 지베렐린 디엔에이(dna) 및 이들의 사용 방법(recombinant gibberellin dna and uses thereof)
ZA952242B (en) Recombinant viruses their preparation and their use in gene therapy
IL114688A0 (en) Vectors and transformed host cells
FR2718749B1 (fr) Vecteurs viraux et utilisation en thérapie génique.
KR960010685A (ko) 펩티드 및 그 용도

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20080630